Amgen's Lung Cancer Drug Tarlatamab Wins China Approval, Tapping Multi-Billion Dollar Market
AMGN sits 36% above its 52-week low of $261.43.
Summary
Amgen's lung cancer drug tarlatamab, known as Imdelltra in the U.S., has secured approval from China's National Medical Products Administration for extensive-stage small cell lung cancer. This significant regulatory win opens a major new market for Amgen, with analysts projecting over $2 billion in annual sales potential for the drug. The approval strengthens Amgen's oncology pipeline and provides a material boost to its long-term revenue outlook, following recent positive Phase 3 results for other key drugs like Repatha and Tepezza. Traders will be watching for details on the drug's launch timeline and pricing strategy in China to assess the full financial impact.
At the time of this announcement, AMGN was trading at $356.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $191.7B. The 52-week trading range was $261.43 to $391.29. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.